Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial

RCT (n=585) found capecitabine (CP) when added to 3 cycles of docetaxel followed by 3 cycles of a 3-drug anthracycline combination containing CP instead of 5-FU improved disease-free survival (86.3% v 80.4% at 5yrs;HR,0.66;95% CI,0.44-0.99;p= 0.044), without new safety concerns.

Journal of Clinical Oncology